Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) PEG Ratio: N/A (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
65 GF Score
Price ¥15.42
GF Value ¥13.72
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Jiangsu Lianhuan Pharmaceutical Co's PE Ratio without NRI is 0.00. Jiangsu Lianhuan Pharmaceutical Co's 5-Year EBITDA growth rate is -18.30%. Therefore, Jiangsu Lianhuan Pharmaceutical Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Jiangsu Lianhuan Pharmaceutical Co's PEG Ratio or its related term are showing as below:


During the past 13 years, Jiangsu Lianhuan Pharmaceutical Co's highest PEG Ratio was 8.40. The lowest was 0.85. And the median was 1.97.


SHSE:600513's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.715
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Jiangsu Lianhuan Pharmaceutical Co  (SHSE:600513) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Jiangsu Lianhuan Pharmaceutical Co PEG Ratio Related Terms


Jiangsu Lianhuan Pharmaceutical Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co PEG Ratio Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.56 0.96 1.41 5.83 0.00

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.93 0.00 0.00 0.00 0.00

SHSE:600513 vs ZTS, UTHR: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Lianhuan Pharmaceutical Co PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's PEG Ratio falls into.


SHSE:600513
65GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Lianhuan Pharmaceutical Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Jiangsu Lianhuan Pharmaceutical Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-18.30
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.42 is trading 12.4% above its estimated GF Value™ of ¥13.72. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600513:

  • PEG Ratio: N/A
  • GF Value™: ¥13.72 vs. price of ¥15.42 (12.4% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
65GF Score

Get the complete analysis for SHSE:600513

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.42
Price
¥13.72
GF Value